MNKD
MannKind Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -10.5% ·
share flow -4.0% ·
net new positions -11.8%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 106.41K | $325,595 | n/a | n/a |
| Q2 2026 | 90 | 0 | 122.90M | $522.94M | +9 | −11 |
| Q1 2026 | 95 | -6 | 143.26M | $351.80M | +6 | −12 |
| Q4 2025 | 99 | +3 | 133.27M | $755.65M | +3 | n/a |
| Q3 2025 | 17 | -2 | 89.45M | $480.37M | +1 | −3 |
| Q2 2025 | 16 | 0 | 83.27M | $311.43M | n/a | n/a |
| Q1 2025 | 13 | 0 | 35.19M | $177.04M | n/a | n/a |
| Q4 2024 | 13 | 0 | 35.66M | $229.30M | n/a | n/a |
| Q3 2024 | 12 | +1 | 19.40M | $122.05M | +1 | n/a |
| Q2 2024 | 11 | n/a | 20.14M | $105.14M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 28.71M | -1.3% | $154.17M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passive) | 17.63M | -2.9% | $94.68M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 10.74M | -0.1% | $57.67M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 7.39M | -3.0% | $39.67M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | JPMorgan Chase ✦ | 4.10M | n/a | $21.99M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 6 | Morgan Stanley ✦ | 3.85M | n/a | $20.68M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 7 | Wellington Management ✦ | 3.47M | +316.2% | $18.62M | 0.0% | ▲ Add | 6 | SEC ↗ ×6 |
| 8 | Fidelity (FMR) ✦ | 3.32M | -16.0% | $17.82M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 2.01M | -20.4% | $10.79M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 1.95M | n/a | $10.47M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Adage Capital Partners ✦ | 1.69M | New | $9.10M | 0.0% | New | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 1.30M | +601.1% | $6.98M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | D. E. Shaw & Co. ✦ | 856.95K | -66.0% | $4.60M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Renaissance Technologies ✦ | 850.80K | -39.8% | $4.57M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 736.68K | +1513.0% | $3.96M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 16 | Millennium Management ✦ | 586.54K | -86.9% | $3.15M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 267.94K | +11.1% | $1.44M | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $9.10M | 0.0% |
Exited
| Arrowstreet Capital | $4.11M | was 0.0% |
| Marshall Wace | $1.03M | was 0.0% |
| Gotham Asset Management | $266,247 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 250 holders, 176.45M shares, $430.71M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 39.05K sh · $128,478
Director · 33.56K sh · $127,856
Director · 39.05K sh · $158,547
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology